Patents Assigned to Wellesley College
-
Patent number: 9403791Abstract: The disclosure provides methods and compositions for treating and preventing cancer using 6-substituted coumarin derivatives. The coumarin derivatives of the disclosure have substituents at the 6-position with five carbon atoms or greater. The coumarin derivatives may be further substituted and may be 3,4-dihydrocoumarins. In preferred embodiments, the coumarin derivatives of the disclosure are used to treat pancreatic cancer.Type: GrantFiled: March 14, 2014Date of Patent: August 2, 2016Assignee: Wellesley CollegeInventor: Dora Carrico-Moniz
-
Patent number: 9388155Abstract: The disclosure provides methods and compositions for treating and preventing cancer using 6-substituted coumarin derivatives. The coumarin derivatives of the disclosure have substituents at the 6-position with five carbon atoms or greater. The coumarin derivatives may be further substituted and may be 3,4-dihydrocoumarins. In preferred embodiments, the coumarin derivatives of the disclosure are used to treat pancreatic cancer.Type: GrantFiled: March 14, 2014Date of Patent: July 12, 2016Assignee: Wellesley CollegeInventor: Dora Carrico-Moniz
-
Patent number: 6846933Abstract: The present invention relates to novel antimycobacterial compounds and in particular to antimycobacterial compounds comprised of Schiff base, diacylhydrazine, sulfur-containing diacylhydrazine and oxadiazoline congeners of isonicotinic acid hydrazide. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.Type: GrantFiled: October 30, 2000Date of Patent: January 25, 2005Assignee: The Board of Trustees of Wellesley CollegeInventor: Michael J. Hearn
-
Patent number: 6600063Abstract: The present invention relates to novel antimycobacterial compounds and in particular to antimycobacterial compounds comprised of derivatives of phenyl 4-aminosalicylate. This invention further relates to methods for their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them. The novel methods of the invention yield derivatives of phenyl 4-aminosalicylate on a multi-gram scale and in high purity for subsequent biological evaluation in drug discovery.Type: GrantFiled: October 23, 2000Date of Patent: July 29, 2003Assignee: Board of Trustees of Wellesley CollegeInventor: Michael J. Hearn
-
Patent number: 6307978Abstract: A system is disclosed for error diffusion dithering. The system includes an input for receiving an input matrix representative of image data, and a plurality of processors. The plurality of processors processes the input matrix and provides output data. Each of the processors is in communication with at least a portion of the input matrix. At least one processor processes a portion of the input matrix defined at least in part by a substantially diagonal edge within the image matrix.Type: GrantFiled: June 3, 1998Date of Patent: October 23, 2001Assignee: Wellesley CollegeInventor: Panagiotis Takis Metaxas
-
Patent number: 5998578Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells. The subject invention further concerns antibodies that are immunoreactive with human IL-1.beta. proteins.Type: GrantFiled: June 7, 1995Date of Patent: December 7, 1999Assignees: New England Medical Center Hospitals, Inc., Massachusetts Institute of Technology, Trustees of Tufts College, Wellesley CollegeInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff, deceased
-
Patent number: 5985657Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: June 7, 1995Date of Patent: November 16, 1999Assignees: New England Medical Center Hospitals, Tufts College, Wellesley College, Massachusetts Institute of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5849999Abstract: Disclosed is a transgenic non-human mammal that expresses in its brain a transgene encoding an APP-C100 polypeptide with the flag amino acid sequence fused to the amino terminus of the APP-C100. This transgenic non-human mammal is an improved in vivo model for Alzheimer's disease-like neuropathology and associated cognitive impairment. The improvement includes accelerated development of AD-like neuropathology and cognitive impairment. The AD-like neurodegeneration and associated cognitive impairment in mice produced according to this invention appear at least six months sooner than they appear in APP-C100-expressing transgenic mice.Type: GrantFiled: October 16, 1996Date of Patent: December 15, 1998Assignees: The McLean Hospital Corporation, Wellesley CollegeInventors: Rachael L. Neve, Joanne Berger-Sweeney
-
Patent number: 5681933Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. The subject invention further concerns antibodies that are immunoreactive with human IL-1.beta. proteins. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: June 1, 1993Date of Patent: October 28, 1997Assignees: New England Med. Center Hospitals, Tufts College, Wellesley College, Mass. Inst. of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5510462Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes-stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: April 25, 1988Date of Patent: April 23, 1996Assignees: New England Medical Centers Hospitals, Inc., Trustees of Tufts College, Wellesley College, Massachusetts Institute of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5077219Abstract: The subject invention concerns truncated human Il-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.Type: GrantFiled: August 21, 1990Date of Patent: December 31, 1991Assignees: New England Medical Center Hospitals, Wellesley College, Tufts College, MITInventors: Philip E. Auron, Andrew C. Webb, Lee Gehrke, Charles A. Dinarello, Lanny J. Rosenwasser, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5001057Abstract: The subject invention concerns truncated human IL-1 cDNA sequences which encode biologically-active novel human IL-1 proteins. These truncated human IL-1 cDNA sequences can be obtained by genetic engineering procedures using a clone of human IL-1 cDNA, having the accession number NRRL B-15770, as a starting material. The truncated human IL-1 cDNA sequences of the subject invention are contained in specified plasmids whose constructions are described in detail. Biologically-active human IL-1 proteins are useful to induce the production of IL-2 by activated T-cells. They also act on B-cells and NK-cells.Type: GrantFiled: April 21, 1988Date of Patent: March 19, 1991Assignees: New England Medical Center, Tufts College, Wellesley College, MITInventors: Philip E. Auron, Andrew C. Webb, Lee Gehrke, Charles A. Dinarello, Lanny J. Rosenwasser, Alexander Rich, Sheldon M. Wolff
-
Patent number: 4923807Abstract: The invention is directed to an Arg-Serpin human plasminogen activator inhibitor designated PAI-2. This protein is prepared via recombinant DNA means. The invention also includes other serpins which can be made by amino acid substitutions or deletions in conserved regions of PAI-1 and PAI-2, as shown in FIG. 4. The proteins of the invention can be used to inhibit, or at least modulate, human plasminogen activator activity in a variety of physiological conditions, e.g., fibrinolysis, tumor metastasis, and tumor growth.Type: GrantFiled: February 6, 1987Date of Patent: May 8, 1990Assignees: New England Medical Center Hospitals Inc., Tufts College, Wellesley College, MITInventors: Andrew C. Webb, Philip E. Auron
-
Patent number: 4766069Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: January 8, 1987Date of Patent: August 23, 1988Assignees: New England Medical Center, Tufts College, Wellesley College, MITInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff